Enforcement Report- Week of October 27, 2021
Enforcement Report - Week of May 8, 2019
Enforcement Report - Week of October 17, 2018
Amlodipine and Valsartan Tablets, Glipizide Extended-Release Tablets, Dexamethasone Tablets, Argatroban Injection, Fluphenazine Decanoate Injection, Meropenem Injection, Mycophenolate Mofetil Injection, Levothyroxine Sodium Injection; Shire-NPS Pharmaceuticals, Inc. v. Par Pharmaceutical et al.
Zydus Pharms USA Inc.'s Generic Glipizide Receives Approval In The US
Pharma firm Zydus Cadila today said it has received final approvals from the US health regulator to market four generic products in America. The company has received approvals from the United States Food and Drug Administration (USFDA) for Olanzapine tablets, Glipizide extended-release tablets, Voriconazole for injection and Fluocinonide topical solution, Zydus Cadila said in a statement.
Aurobindo Pharma’s Generic Glipizide Receives Approval In US
Enforcement Report - Week of March 22, 2017
Some weeks back, generics maker Mylan recalled about 1,300 bottles, containing more than 1.3 million tablets, of the 5-mg dose of the Type 2 diabetes med Glipizide. The recall was voluntarily initiated because there was a chance that tablets in a 10-mg dose might have gotten into the bottles. Now the drugmaker has issued two more recalls of an entirely different med that might also contain some of the stray tablets.
Enforcement Report - Week of March 8, 2017